Insulin glargine and malignancy: an unwarranted alarm-Reference-Cited by-同舟云学术

Insulin glargine and malignancy: an unwarranted alarm

Published:2009-08 Issue:9689 Volume:374 Page:511-513
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Pocock Stuart J,Smeeth Liam

Publisher

Elsevier BV

Subject

General Medicine

Reference8 articles.

1. Does diabetes therapy influence the risk of cancer?;Smith;Diabetologia,2009

2. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study;Hemkens;Diabetologia,2009

3. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes;Currie;Diabetologia,2009

4. Insulin glargine use and short-term incidence of malignancies—a population-based follow-up study in Sweden;Jonasson;Diabetologia,2009

5. Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study;Rosenstock;Diabetologia,2009

Cited by 125 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug repositioning in thyroid cancer treatment: the intriguing case of anti-diabetic drugs;Frontiers in Pharmacology;2023-12-11

2. Insulin glargine use and cancer risk among patients with type 2 diabetes mellitus: a real-world study in Shanghai, China;International Journal of Diabetes in Developing Countries;2023-08-10

3. Se-Glargine II. Native Function of a Basal Insulin Analog Stabilized by an Internal Diselenide Bridge;2023-06-24

4. Obesity, diabetes, and cancer: epidemiology, pathophysiology, and potential interventions;Archives of Endocrinology and Metabolism;2023

5. Use of Antihyperglycemic Drugs and Risk of Cancer in Patients with Diabetes;Current Oncology Reports;2022-11-29